ESC 2022 Late-breaker Discussion: The DELIVER Trial

Подробнее о видео

Watch on Radcliffe Cardiology: *hjpimw*_ga*MTE1NzYxMzg0NC4xNjYxNTg2ODk0*_ga_T874FCJ3LG*MTY2MTY5NTgwMC4xNi4xLjE2NjE2OTc3MjEuMC4wLjA.&utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_hvs_solomon

Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Scott D Solomon (Brigham & Women's Hospital & Harvard Medical School, US) to discuss one of the most awaited trials of 2022, DELIVER (NCT03619213).

This study assessed the effect of dapagliflozin 10 mg versus placebo, given once daily in addition to background regional standard of care therapy, including treatments to control co-morbidities, in reducing the composite of CV death or heart failure events.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.